Follow the people · Insider
Ken Takanashi
Ken Takanashi files insider transactions with the SEC as a director of Wave Life Sciences (WVE). We hold 1 disclosed purchase or sale filed since 18 November 2015, 1 of them in the last 90 days.
- Files forWVE
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure13 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 14 August 2015 — 11 August 2026Director · Wave Life Sciences (WVE)22 Form 4 lines · source: SEC Form 4
- Filed 17 September 2019 — 8 June 2023Director and 10% owner · Satsuma Pharmaceuticals (STSA)13 Form 4 lines · source: SEC Form 4
Everything they disclosed
35 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 3,864 shares of Wave Life SciencesSEC Form 413 August 2026Common Stock · traded 11 August 2026 · filed 13 August 2026
- converted 3,901,348 shares of Wave Life SciencesSEC Form 426 March 2026Ordinary Shares · traded 23 March 2026 · filed 26 March 2026
- converted 3,901,348 shares of Wave Life Sciences (a derivative holding)SEC Form 426 March 2026Series A Preferred Shares · traded 23 March 2026 · filed 26 March 2026
- converted 3,901,348 shares of Wave Life Sciences (a derivative holding)SEC Form 426 March 2026Series A Preferred Shares · traded 23 March 2026 · filed 26 March 2026
- converted 3,901,348 shares of Wave Life SciencesSEC Form 426 March 2026Ordinary Shares · traded 23 March 2026 · filed 26 March 2026
- was granted 76,200 shares of Wave Life Sciences (a derivative holding)SEC Form 413 August 2025Share Option (right to buy) · traded 11 August 2025 · filed 13 August 2025
- was granted 12,700 shares of Wave Life SciencesSEC Form 413 August 2025Ordinary Shares · traded 11 August 2025 · filed 13 August 2025
- ▼ sold on the open market 4,872 shares of Wave Life SciencesSEC Form 47 August 2025Ordinary Shares · traded 5 August 2025 · filed 7 August 2025
- was granted 32,230 shares of Wave Life Sciences (a derivative holding)SEC Form 414 August 2024Share Option (right to buy) · traded 12 August 2024 · filed 14 August 2024
- was granted 16,115 shares of Wave Life SciencesSEC Form 414 August 2024Ordinary Shares · traded 12 August 2024 · filed 14 August 2024
- was granted 45,000 shares of Wave Life Sciences (a derivative holding)SEC Form 49 August 2023Share Option (right to buy) · traded 7 August 2023 · filed 9 August 2023
- returned to the issuer 10,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 48 June 2023Stock Option (right to buy) · traded 8 June 2023 · filed 8 June 2023
- returned to the issuer 20,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 48 June 2023Stock Option (right to buy) · traded 8 June 2023 · filed 8 June 2023
- returned to the issuer 30,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 48 June 2023Stock Option (right to buy) · traded 8 June 2023 · filed 8 June 2023
- ▲ bought on the open market 22,053,581 shares of Satsuma PharmaceuticalsSEC Form 48 June 2023Common Stock, $0.0001 par value · traded 6 June 2023 · filed 8 June 2023
- was granted 30,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 49 December 2022Stock Option (Right to Buy) · traded 3 June 2022 · filed 9 December 2022
- was granted 21,000 shares of Wave Life Sciences (a derivative holding)SEC Form 417 August 2022Share Option (right to buy) · traded 15 August 2022 · filed 17 August 2022
- was granted 30,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 47 June 2022Stock Option (Right to Buy) · traded 3 June 2022 · filed 7 June 2022
- was granted 42,000 shares of Wave Life Sciences (a derivative holding)SEC Form 418 August 2021Share Option (right to buy) · traded 16 August 2021 · filed 18 August 2021
- was granted 20,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 47 December 2020Stock Option (Right to Buy) · traded 3 December 2020 · filed 7 December 2020
- was granted 10,500 shares of Wave Life Sciences (a derivative holding)SEC Form 420 August 2020Share Option (right to buy) · traded 18 August 2020 · filed 20 August 2020
- was granted 10,000 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 416 June 2020Stock Option (Right to Buy) · traded 12 June 2020 · filed 16 June 2020
- converted 33,741 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 417 September 2019Series A Preferred Stock · traded 17 September 2019 · filed 17 September 2019
- converted 307,110 shares of Satsuma Pharmaceuticals (a derivative holding)SEC Form 417 September 2019Series B Preferred Stock · traded 17 September 2019 · filed 17 September 2019
- converted 33,741 shares of Satsuma PharmaceuticalsSEC Form 417 September 2019Common Stock, $0.0001 par value · traded 17 September 2019 · filed 17 September 2019
- converted 307,110 shares of Satsuma PharmaceuticalsSEC Form 417 September 2019Common Stock, $0.0001 par value · traded 17 September 2019 · filed 17 September 2019
- ▲ bought on the open market 233,333 shares of Satsuma PharmaceuticalsSEC Form 417 September 2019Common Stock, $0.0001 par value · traded 17 September 2019 · filed 17 September 2019
- was granted 10,500 shares of Wave Life Sciences (a derivative holding)SEC Form 416 August 2019Share Option (right to buy) · traded 15 August 2019 · filed 16 August 2019
- was granted 9,000 shares of Wave Life Sciences (a derivative holding)SEC Form 415 August 2018Share Option (right to buy) · traded 13 August 2018 · filed 15 August 2018
- was granted 9,000 shares of Wave Life Sciences (a derivative holding)SEC Form 417 August 2017Share Option (right to buy) · traded 10 August 2017 · filed 17 August 2017
- was granted 9,000 shares of Wave Life Sciences (a derivative holding)SEC Form 414 November 2016Share Option (right to buy) · traded 10 November 2016 · filed 14 November 2016
- converted 161,663 shares of Wave Life SciencesSEC Form 418 November 2015Ordinary Shares · traded 16 November 2015 · filed 18 November 2015
- ▲ bought on the open market 125,000 shares of Wave Life SciencesSEC Form 418 November 2015Ordinary Shares · traded 16 November 2015 · filed 18 November 2015
- ▲ bought on the open market 161,663 shares of Wave Life Sciences (a derivative holding)SEC Form 418 November 2015Series B Preferred Shares · traded 14 August 2015 · filed 18 November 2015
- converted 161,663 shares of Wave Life Sciences (a derivative holding)SEC Form 418 November 2015Series B Preferred Shares · traded 16 November 2015 · filed 18 November 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.